Recently it was announced that Fluor Corporation of Irving, TX landed a $1.2 billion contract to design and build the $2 billion manufacturing facility for Novo Nordisk‘s diabetes API (Active Pharmaceutical Ingredient) in North Carolina.
News reports reveal the world-class facility designed to provide diabetes patients with modern treatments is the largest investment in a life sciences facility in the history of North Carolina. Senior VP at Novo Nordisk, Morten Nielsen, said the pharmaceutical company chose Fluor for the company’s largest, most critical project in its history based on Fluor’s technical competence in the life sciences industry, strong safety culture, and ability to deliver the full scope of work.
At the peak of the facility’s construction it is expected that approximately 2,500 subcontractors and craft employees will work on the project, which is expected to provide approximately 700 new jobs upon completion. The new facility will manufacture life-saving medications for diabetes patients around the globe; its size will be equal to about seven football fields, containing more than 830,000 square feet.
Completion of the new API facility is scheduled for mid-2019. Headquartered in Denmark, Novo Nordisk markets its pharmaceutical products in over 180 countries, and is a global leader in diabetes care and innovation. Some of the company’s products include Victoza®, Levemir®, Tresiba®, Flex Touch®, and FlexPen®.
REA JET U.S. is a leader in the pharma coding and marking solutions industry. We understand that in today’s technology-advanced world, change is a constant in nearly every industry. For all of your industrial printing needs count on REA JET for quality, cost-effective solutions that integrate easily with your current infrastructure.